Merck has formed an oncology collaboration with Eisai to jointly develop and commercialize the latter's Lenvima cancer treatment both as a monotherapy as well as in combination with its anti-PD-1 therapy, Keytruda, for various types of cancer.
Original Article: Merck, Eisai enter into $5.76bn oncology alliance